CapSys Group’s latest global research, Re-thinking Market Access, identified six success requirements to enable Market Access to strategically withstand market pressures and achieve Market Access Excellence. Market Access leaders and experts at CapSys identified four technical and two organizational prerequisites for market access success. These success requirements are described in detail throughout the Re-thinking Market Access series of insights. The technical success requirements include an understanding of stakeholders and the market access landscape (1), evidence generation (2), stakeholder engagement (3), and value demonstration and communication (4). The organizational aspects which underpin these technical success factors include organizational skills and capabilities (5) and organizational setup (6). Based on these valuable insights, experts at CapSys developed the CapSys Market Access Excellence Canvas, a (self-)assessment tool and framework to enable Market Access professionals to assess their organizations and prioritize actions on the path to achieving Market Access Excellence.
Re-thinking Market Access is CapSys’ global study of Market Access, which aims to understand the challenges and trends that the Market Access function faces today. The research derived implications and levers of success for organizations on a strategic and practical level. Subsequently, CapSys provides a systematic approach based on the success levers to assess performance and develop solutions to overcome the challenges.
Through interviews with global and regional Market Access experts and key opinion leaders (KOLs) from pharmaceutical and life sciences organizations, CapSys developed the Market Access Excellence Canvas. The canvas provides a solid basis for Market Access executives to make decisions in order to develop key technical and organizational factors on the path to Market Access Excellence.
CapSys developed the Market Access Excellence Canvas harnessing CapSys’ key expertise and valuable contributions from Market Access experts in global pharmaceutical and life sciences organizations. CapSys provides expertise across business strategy and planning, Market Access Excellence, business transformation, and capabilities development. The Canvas is a tool designed to help Market Access executives assess their organization and to serve as a framework for developing a world-class Market Access function and achieving Market Access Excellence (Figure 2).
The CapSys Market Access Excellence Canvas pack contains three components (Figure 2):
The (Self-)assessment Canvas is a list of guiding questions for (self-)assessment to discuss within your Market Access team. For best practice, the (self-)assessment must be conducted as a team effort rather than as an individual exercise. To further strengthen the assessment, cross-functional input (i.e. from Medical Affairs or Commercial teams) is necessary.
The Planning Canvas is a template designed for Market Access executives to carefully list the organization’s strengths and shortcomings and identify development areas.
A template for Market Access executives to list the required actions to build on strengths and to address development areas. The template also enables prioritization of those actions.
As well as assessing the current fitness of the organization, the CapSys Market Access Excellence Canvas should be used to continuously evaluate its progress.
Sign up and download the components of the CapSys Market Access Excellence Canvas pack here.
This is the last in a series of eight insight articles based on CapSys’ global Re-thinking Market Access study and focused on Market Access Excellence in pharma and life sciences. The introductory article provides an overview of the study and its outcomes. The six following insight articles (Insights 1-6) provide key content and food for thought on the six success requirements for Market Access Excellence, including observed common shortcomings and improvement opportunities. This final article in the series provides a framework and (self-)assessment tool, the Market Access Excellence Canvas, to assess your organization’s maturity level and potential gaps to close on the journey to achieve Market Access Excellence. Sign up here for upcoming articles in the Re-thinking Market Access series.
For more detailed information on the Re-thinking Market Access study or to share your opinion on what makes a successful Market Access function, please get in touch with the CapSys experts, Patrick and Kenneth.
Consultant at CapSys Group
CapSys provides top-tier management consulting support on strategy and execution topics. We are sector experts in Life Sciences and have a unique business model that provides flexibility and reduces risk for clients while maximizing impact.
At CapSys Group, we support our Life Science clients to overcome their most difficult growth challenges by:
- Strategic advisory to unlock growth
- Embedding capabilities to sustain value-adding growth
- Enabling execution & change to activate growth
CapSys Group’s ‘Re-thinking Market Access: An Overview of Key Challenges for the Pharmaceutical Industry and a Framework for Success’ is a global study of Market Access. The study aims to understand the current challenges and trends that the Market Access function is facing today, derive implications and levers of success for the organization, both on a strategic and practical level, and provide a systematic approach along the success levers to assess performance and develop solutions to overcome the challenges.
‘Re-thinking Market Access’ was conducted through interviews with global and regional industry experts and key opinion leaders in Market Access, from small to large pharmaceutical and life sciences organizations. Contributors had broad therapeutic area expertise, including oncology, orphan diseases, and dermatology.
There is a wealth of additional insights from the expert interviews. If you want an in-depth discussion on the gathered insights or a conversation on the implications for your company, please get in touch with our CapSys experts, Patrick Koller and Kenneth Weissmahr.